Abstract
Objective: To evaluate the efficacy and safety of Shenfu injection in the treatment of septic cardiomyopathy. Methods: Literatures on Shenfu injection for the treatment of sepsis published from the establishment of each database to December 31, 2020, were searched by computer; Cochrane risk-of-bias tool was used for evaluating the quality of literatures, and Review Manager 5.4 software was used for meta-analysis. Results: Twenty random controlled trials (RCTs) were included, with a total of 1,179 patients; the meta-analysis showed that the routine treatment of Western medicine combined with Shenfu injection can reduce the 28-day mortality, the length of hospital stay, cardiac troponin I (cTnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as improve the left ventricular ejection fraction (LVEF) with low incidence of adverse reactions. Conclusion: Western medicine combined with Shenfu injection can further reduce myocardial injury in patients with sepsis and improve cardiac function as well as the prognosis of patients with septic cardiomyopathy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
